ATOME has had a price target of 181p and 'buy' recommendation reiterated by house broker Liberum following the appointment of AECOM to oversee its Villeta project in Paraguay.
The AIM-listed group will leverage AECOM’s multi-disciplinary resource pool and significant experience in delivering large-scale projects ahead of first production by 2025.
Condor Gold PLC (AIM:CNR, TSX:COG, OTC:CNDGF) said it raised about £3.25mln via a private placement to help fund a feasibility study for the La India project in Nicaragua.
The placement represented about 7.9% of the company's existing issued shares.
Open Orphan PLC (AIM:ORPH, OTC:OPORF) said its hVIVO subsidiary won its third significant deal in under a month as it announced a £7.2mln human challenge contract with an unnamed ‘top five’ global pharma group.
The clinical research group will test the pharma's orally administered antiviral product, using hVIVO's respiratory syncytial virus (RSV) Human Challenge Study Model.
ANGLE PLC (AIM:AGL, OTCQX:ANPCY)said its Parsortix liquid biopsy system was used in research that could aid a better understanding of the development of prostate cancer. A team from King's College London assessed the role of invasive cellular protrusion in potentially causing the spread of the disease, a process called metastasis. The ANGLE device was used to harvest circulating tumour cells. For more information click here.
IXICO PLC (AIM:IXI, OTC:PHYOF), the neuroimaging contract research group, said an existing client has asked it to extend the breadth of services is provides to a phase I/II trial in Huntington’s disease. The new work worth an additional £800,000 over four years.
Four directors of Oracle Power PLC (AIM:ORCP), Naheed Memon, David Hutchins, Andreas Migge, and Mark Steed bought shares in the company under an existing share purchase plan. The price paid was 0.305p per share.